Related Experiment Videos
Prognostic factors in symptomatic Waldenstrom's macroglobulinemia
Giampaolo Merlini1, Luca Baldini, Chiara Broglia
1Research Biotechnology Laboratories, and Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo, Pavia, Italy.
Seminars in Oncology
|April 30, 2003
Summary
This study identified key prognostic factors for Waldenstrom's macroglobulinemia (WM). Age, hemoglobin, and albumin levels predict survival, with beta(2)-microglobulin being the strongest determinant in a subgroup analysis.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Waldenstrom's macroglobulinemia (WM) is a rare B-cell lymphoproliferative disorder.
- Identifying prognostic factors is crucial for tailoring treatment strategies in symptomatic WM patients.
Purpose of the Study:
- To analyze the prognostic value of presenting features in homogeneously treated patients with symptomatic WM.
- To evaluate established scoring systems and identify key predictors of survival.
Main Methods:
- Retrospective analysis of 215 symptomatic WM patients treated with alkylating agent-based chemotherapy.
- Multivariate Cox regression analysis to identify prognostic determinants.
- Evaluation of Dhodapkar, Morel, and Gobbi scoring systems.
Main Results:
- Median overall survival was 77.2 months.
- Age, hemoglobin, and serum albumin levels were significant predictors of survival.
- Beta(2)-microglobulin emerged as the strongest prognostic factor in a subgroup analysis.
- All tested scoring systems effectively stratified patients into distinct prognostic groups.
Conclusions:
- A prognostic index incorporating age, hemoglobin, and albumin can guide therapeutic decisions.
- Beta(2)-microglobulin is a critical prognostic marker for WM patients diagnosed after 1990.
- These findings aid in risk stratification and personalized treatment for WM.